Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity
of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after
lymphodepletion consisting of cyclophosphamide and fludarabine.
Lymphoma, Phase I
Phase I
Adults
Mol. targeted/Immunotherapy/Biologics
Not Available
Oluwole, Olalekan
International
Vanderbilt University
05-08-2024
Treatment
VICC-DTCTT23155P
NCT04637763

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

Age greater than or equal to 18 at the time of enrollment

Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior standard of care

Eastern Cooperative Oncology Group performance status 0 or 1

Adequate hematologic, renal, liver, cardiac and pulmonary organ function



Exclusion Criteria:

Prior therapy with an anti-CD19 targeting agent

Active or chronic graft versus host disease requiring therapy

Prior allogeneic stem cell transplantation

Central nervous system (CNS) lymphoma, prior CNS malignancy

Prior seizure disorder, cerebrovascular ischemia, dementia, cerebellar disease or autoimmune disease with CNS involvement.

Primary immunodeficiency

Current or expected need for systemic corticosteroid therapy

Current thyroid disorder. Hypothyroidism controlled with stable hormone replacement is permitted

Other malignancy within 2 years of study entry, except curatively treated malignancies or malignancies with low risk of recurrence

Unwillingness to follow extended safety monitoring

To learn more about any of our clinical
trials, call 615-936-8422.